← Eichor
Condition: Advanced Esophageal Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Esophageal Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinom
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT07188103A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05392413Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
NA · 1 location(s) · Anhui Provincial Hospital · NCT06602843Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Phase 1/Phase 2 · 22 location(s) · Merck Sharp & Dohme LLC · NCT07405151A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 14 location(s) · Kyowa Kirin Co., Ltd. · NCT06248411Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Phase 1/Phase 2 · 44 location(s) · Merck Sharp & Dohme LLC · NCT06780111Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06339619Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT03964753A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06718205DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Pos
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06885814A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial
Phase 1 · 12 location(s) · EvolveImmune United, Inc · NCT07217171A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/Phase 2 · 15 location(s) · Terremoto Biosciences Inc. · NCT07109726Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 · 1 location(s) · Akeso · NCT07263919
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.